The abstract describes contradictory outcomes where some exported JDPs (DnaJB11, DnaJB1, DnaJB6) enhance proteostasis while others (DnaJB8) increase chemotherapy resistance in cancer. The molecular determinants of these opposing functional outcomes remain unexplained, limiting therapeutic applications. Gap type: contradiction Source paper: Extracellular chaperone networks and the export of J-domain proteins. (2023, The Journal of biological chemistry, PMID:36581212)
Landscape Summary: What determines whether exported JDPs enhance proteostasis vs. confer pathological advantages like chemoresistance? is a 0.83 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What determines whether exported JDPs enhance proteostasis vs. confer pathological advantages like chemoresistance? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: